Pharmacokinetics and pharmacodynamics of alirocumab in patients with autosomal dominant hypercholesterolemia associated with PCSK9 gain-of-function or ApoB loss-of-function mutations

被引：0

作者：

Hopkins, P. N. ^{[1
]}

Krempf, M. ^{[2
]}

Bruckert, E. ^{[3
]}

Luc, G. ^{[4
]}

Donahue, S. ^{[5
]}

Yang, F. ^{[5
]}

Zhang, Y. ^{[5
]}

Dicioccio, A. T. ^{[5
]}

机构：

[1] Univ Utah, Sch Med, Salt Lake City, UT USA

[2] CHU Nantes, Hop Nord Laennec, St Herblain, France

[3] Hosp Pitie Salpetriere, Paris, France

[4] Univ Lille 2, Lille, France

[5] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

来源：

EUROPEAN HEART JOURNAL | 2018年 / 39卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

352

引用

页码：49 / 49

页数：1

共 50 条

[21] Familial hypobetalipoproteinemia caused by homozygous loss-of-function mutations in PCSK9: A case report
Kudo, Takanori
Sasaki, Kei
Tada, Hayato
JOURNAL OF CLINICAL LIPIDOLOGY, 2022, 16 (05) : 596 - 600
[22] Analysis of sperm galactosyltransferase through gain-of-function and loss-of-function mutations
Shur, B
Lu, QX
Shi, XD
Paruchuru, K
Miller, D
MOLECULAR BIOLOGY OF THE CELL, 1998, 9 : 7A - 7A
[23] Using SIFT and PolyPhen to Predict Loss-of-Function and Gain-of-Function Mutations
Flanagan, Sarah E.
Patch, Ann-Marie
Ellard, Sian
GENETIC TESTING AND MOLECULAR BIOMARKERS, 2010, 14 (04) : 533 - 537
[24] PRODUCTION AND PURIFICATION OF RECOMBINANT PCSK9 TO STUDY PCSK9 GAIN OF FUNCTION (GOF) AND LOSS OF FUNCTION (LOF) MUTANTS
Chemello, K.
Benito Vicente, A.
Larrea Setubal, A.
Martin, C.
Lambert, G.
ATHEROSCLEROSIS, 2018, 275 : E165 - E165
[25] Loss-of-function, gain-of-function and dominant-negative mutations have profoundly different effects on protein structure
Gerasimavicius, Lukas
Livesey, Benjamin J.
Marsh, Joseph A.
NATURE COMMUNICATIONS, 2022, 13 (01)
[26] Loss-of-function, gain-of-function and dominant-negative mutations have profoundly different effects on protein structure
Lukas Gerasimavicius
Benjamin J. Livesey
Joseph A. Marsh
Nature Communications, 13
[27] Loss-of-function mutation of PCSK9 as a protective factor in the clinical expression of familial hypercholesterolemia A case report
Bayona, Ane
Arrieta, Francisco
Rodriguez-Jimenez, Carmen
Cerrato, Francisco
Rodriguez-Novoa, Sonia
Fernandez-Lucas, Milagros
Gomez-Coronado, Diego
Mata, Pedro
MEDICINE, 2020, 99 (34)
[28] Loss-of-Function and Gain-of-Function Consequences of GATA2 Disease Mutations
Katsumura, Koichi Ricardo
Liu, Peng
Mehta, Charu
Hewitt, Kyle J.
Soukup, Alexandra
de Andrade, Isabela J. Fraga
Ranheim, Erik A.
Johnson, Kirby D.
Bresnick, Emery H.
BLOOD, 2019, 134
[29] Prediction of gain-of-function and loss-of-function mutations using In Silico Bioinformatics Tools
Ghosh, A.
Navarini, A.
EXPERIMENTAL DERMATOLOGY, 2018, 27 (03) : E41 - E41
[30] MicroRNA-146a Deficiency Prevents PCSK9 Gain-of-Function Mutation-induced Hypercholesterolemia in Mice
Mohammadmoradi, Shayan
Javidan, Aida
Jiang, Weihua
Moorleghen, Jessica
Subramanian, Venkateswaran
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2017, 37

← 1 2 3 4 5 →